Connect your AI

Cogent Biosciences, Inc. COGT PP&E (Net)

PP&E (Net) at other companies

PfizerPFE

$19.4B+5.8%

AmgenAMGN

$8.22B+23.0%

IncyteINCY

$720.17M-5.9%

Tango TherapeuticsTNGX

$6.38M-15.4%

CG OncologyCGON

$15.07M+5,610%

Relay Therapeutics, Inc.RLAY

$1.22M-76.3%

Other financials

Income statement

Operating income-$103.6M-38.3%

Net income-$97.4M-35.2%

EPS (diluted)-$0.53-1.9%

Balance sheet

Cash & equivalents$241.2M+91.4%

Total debt$15.5M-9.4%

Total equity$607.7M+177%

Total assets$903.0M+218%

Cash flow

Operating cash flow-$86.9M-30.6%

CapEx$449.0K-17.9%

Free cash flow-$87.3M-30.2%

Valuation

Market cap$5.9B+816%

Profitability

Operating margin-1,044.3%—

Net margin-950.4%—

FCF margin-184.7%—

Returns & leverage

Return on equity-85.7%+1.7pp

Debt / equity0×-0.1×

Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Cogent Biosciences, Inc.'s PP&E (net)?: Cogent Biosciences, Inc. (COGT) reported PP&E (net) of $5.3M in Q1 2026.
How has Cogent Biosciences, Inc.'s PP&E (net) changed year-over-year?: Cogent Biosciences, Inc.'s PP&E (net) decreased by 17.9% year-over-year, from $6.45M to $5.3M.
What is the long-term trend for Cogent Biosciences, Inc.'s PP&E (net)?: Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s PP&E (net) has grown at a 109.9% compound annual growth rate (CAGR), from $134K to $5.46M.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.